Hospital admissions and direct costs: A comparative study between paliperidone palmitate and oral antipsychotics

被引：0
|
作者：
Soler Iborte, A. [1 ]
Galiano Rus, S. [2 ]
Ruiz Sanchez, J. A. [3 ]
机构：
[1] UGC Jaen Norte, Serv Andaluz Salud, Unidad Salud Mental Comunitaria Linares, Jaen, Spain
[2] Hosp San Juan de la Cruz, UGC Jaen Norte, Serv Andaluz Salud, Jaen, Spain
[3] UGC Jaen Norte, Serv Andaluz Salud, Unidad Salud Mental Comunitaria Ubeda, Jaen, Spain
来源：
EUROPEAN PSYCHIATRY | 2016年 / 33卷
关键词：
D O I：
10.1016/j.eurpsy.2016.01.567
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EW449
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [1] Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
    Schreiner, Andreas
    Aadamsoo, Kaire
    Altamura, A. Carlo
    Franco, Manuel
    Gorwood, Philip
    Neznanov, Nikolaj G.
    Schronen, Juan
    Ucok, Alp
    Zink, Mathias
    Janik, Adam
    Cherubin, Pierre
    Lahaye, Marjolein
    Hargarter, Ludger
    SCHIZOPHRENIA RESEARCH, 2015, 169 (1-3) : 393 - 399
  • [2] Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence
    Morrato, Elaine H.
    Parks, Joe
    Campagna, Elizabeth J.
    Muser, Erik
    Thomas, Deborah S. K.
    Fang, Hai
    Doshi, Dilesh
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (02) : 89 - 99
  • [3] Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics
    Lafeuille, Marie-Helene
    Grittner, Amanda Melina
    Fortier, Jonathan
    Muser, Erik
    Fasteneau, John
    Duh, Mei Sheng
    Lefebvre, Patrick
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (05) : 378 - 389
  • [4] Reduction of hospital admissions in patients treated with palmitate of paliperidone (PP)
    Lopez Velasco, R.
    Campos Mangas, C.
    Artaso Irigoyen, B.
    Velasco, J. J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S508 - S508
  • [5] Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
    Pesa J.A.
    Muser E.
    Montejano L.B.
    Smith D.M.
    Meyers O.I.
    Drugs - Real World Outcomes, 2015, 2 (4) : 377 - 385
  • [6] Paliperidone palmitate versus conventional depots and oral antipsychotics in inpatients with schizophrenia
    Romero Guillena, S. L.
    Mata Saenz, B.
    Fashho Rodriguez, E.
    Casas Barquero, N.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S501 - S502
  • [7] Treatment discontinuation in schizophrenia. Paliperidone palmitate versus oral antipsychotics
    Romero Guillena, S. L.
    De Ingunza Barreiro, E.
    Gotor, F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S503 - S504
  • [8] Paliperidone palmitate vs. oral atypical antipsychotics in schizoaffective disorders
    Sanchez-Alonso, S.
    Mata, L.
    Alvarez, R.
    Iza, M.
    Ovejero, S.
    BIPOLAR DISORDERS, 2015, 17 : 137 - 137
  • [9] Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia
    Yinong Young-Xu
    Duh, Mei Sheng
    Muser, Erik
    DerSarkissian, Maral
    Faust, Elizabeth
    Kageleiry, Andrew
    Bhak, Rachel H.
    Fu, Dong-Jing
    Lefebvre, Patrick
    Shiner, Brian
    JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 (10) : E1332 - +
  • [10] A mirror-image study to compare the efficiency of paliperidone palmitate with oral antipsychotics in schizophrenic patients
    Vincent, P. Philippe
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 151 - 151
12345